Michel van Gelder, MD, PhD, Maastricht University, Maastricht, Netherlands, comments on the relevance of chemoimmunotherapy in the frontline treatment of patients with chronic lymphocytic leukemia (CLL) in the era of novel agents. Dr van Gelder argues that the benefits of frontline targeted therapy in the long term are not well-established. In addition, a shorter treatment with chemoimmunotherapy may lead to fewer adverse events than a longer treatment with novel agents. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.